Exploring RSV prevention among pregnant people and healthcare professionals in Aotearoa, New Zealand

In Aotearoa New Zealand (NZ), RSV causes severe disease in infants, particularly Māori and Pacific infants, and is a high burden on the health system. Although an antenatal RSV vaccine and long-acting monoclonal antibodies are available internationally to prevent disease, they are not yet available in NZ. This study aims to explore the knowledge and perceptions of pregnant people and health care providers regarding RSV preventative options, and strategies for supporting a potential future immunization rollout in NZ. In this mixed-methods study, a cross-sectional survey of health care professionals (HCPs) across NZ and qualitative interviews with recently/pregnant Māori, Pacific, or ethnic minority migrants were conducted. A directed content analytic approach was used for analysis. Most HCPs (79.5%; 159/200) thought there was a high need for universal antenatal RSV vaccination, and 73.5% (147/200) ranked antenatal vaccination as their preferred prevention strategy over either targeted or universal infant monoclonal antibody. However, pharmacists comprised 63% of respondents. Interviewed caregivers (n = 13) would prefer to be offered whichever option had the longest duration of protection. If effectiveness and length of protection were similar, most preferred the antenatal vaccine so their infant was not injected to avoid discomfort or potential side effects their infant may experience. Recommendation from trusted HCPs, access to clear information from credible sources, and accessible and trusted administration settings are critical to supporting immunization acceptance. These insights can inform future implementation of a comprehensive rollout of an equitable preventative immunization program, reducing the risk of severe infant RSV disease.

Authors

Publication Details

Journal
Figshare
Published
2026-11-19
DOI
https://doi.org/10.6084/m9.figshare.35063338
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exploring RSV prevention among pregnant people and healthcare professionals in Aotearoa, New Zealand

Samantha Marsh, Esther J. Willing, Ashleigh Rak, Amber Young et al.
Figshare
Respiratory viral infections research
article

Exploring RSV prevention among pregnant people and healthcare professionals in Aotearoa, New Zealand

Samantha Marsh, Esther J. Willing, Ashleigh Rak, Amber Young, Nadia A. Charania, Noni Richards, Yasmin Mohamed, Margie Danchin, Emma Best, Reem Abbas
article en

Abstract

In Aotearoa New Zealand (NZ), RSV causes severe disease in infants, particularly Māori and Pacific infants, and is a high burden on the health system. Although an antenatal RSV vaccine and long-acting monoclonal antibodies are available internationally to prevent disease, they are not yet available in NZ. This study aims to explore the knowledge and perceptions of pregnant people and health care providers regarding RSV preventative options, and strategies for supporting a potential future immunization rollout in NZ. In this mixed-methods study, a cross-sectional survey of health care professionals (HCPs) across NZ and qualitative interviews with recently/pregnant Māori, Pacific, or ethnic minority migrants were conducted. A directed content analytic approach was used for analysis. Most HCPs (79.5%; 159/200) thought there was a high need for universal antenatal RSV vaccination, and 73.5% (147/200) ranked antenatal vaccination as their preferred prevention strategy over either targeted or universal infant monoclonal antibody. However, pharmacists comprised 63% of respondents. Interviewed caregivers (n = 13) would prefer to be offered whichever option had the longest duration of protection. If effectiveness and length of protection were similar, most preferred the antenatal vaccine so their infant was not injected to avoid discomfort or potential side effects their infant may experience. Recommendation from trusted HCPs, access to clear information from credible sources, and accessible and trusted administration settings are critical to supporting immunization acceptance. These insights can inform future implementation of a comprehensive rollout of an equitable preventative immunization program, reducing the risk of severe infant RSV disease.

Figshare
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon